Category Archives: Ulcerative Colitis

Rangers' Hamels throws four-hitter, defeats Twins 4-1 MINNEAPOLIS -- Longtime Texas Rangers ace Yu Darvish is with the Los Angeles Dodgers now, and Texas is reportedly pushing back left-hander Martin Perez's next start as it sorts through its rotation. The Rangers still have Cole Hamels every fifth game, though. Hamels allowed four hits in his first complete game since Oct. 4, 2015, and Nomar Mazara homered for Texas in a 4-1 victory against the Minnesota Twins on Saturday. A night after 44-year-old Bartolo Colon threw an improbable complete game for Minnesota, Hamels finished off his 16th career complete game by retiring 13 of the last 14 batters he faced and tallying 96 pitches. "It's all about getting in a rhythm, and if I'm able to kind of start that rhythm, then obviously all the better," Hamels said. "But I think there's a lot of guys on this pitching staff that are very talented and obviously have ace-caliber stuff. So it's just kinda waking everybody back up." Hamels (6-1) yielded one unearned run. He struck out five batters and walked one in shutting down the Twins' offense. Entering the game, he owned a 6.35 ERA in six starts against Minnesota, the … Continue reading →

You probably dont call up your doctor after every bout of constipation and diarrhea, but its understandable that youd be concerned if you start experiencing poop problems on the regular. While changes in your bowel movements could simply be due to switching up your diet or catching an intestinal bug, they can also be a sign of a more serious condition that needs treatment. Any change in bowel habits needs to be addressed with a doctor, especially those that occur without changes in diet or in connection with other issues, Bruce Yacyshyn, M.D., a professor in the Division of Digestive Diseases at the University of Cincinnati College of Medicine, tells SELF. Youre probably not crazy about the idea of talking poop with your doctor, buttrust usthey've heard it all before. Here are a few things those doctors want to hear about (though this is by no means an exhaustive list): Sure, diarrhea is never going to feel good, but if you consistently have it with stomach cramping and abdominal pain, it could be a sign of IBS-D, a form of irritable bowel syndrome that causes chronic or recurrent diarrhea. That pain is a big indicator that you might have IBS, … Continue reading →

What if eating fresh mango in addition to drug therapy can help shorten or reduce severity of flares of inflammatory bowel disease? What if it can help prevent precursor lesions from forming? Those are the questions that prompted a study by researchers at Texas A&M University in College Station. Inflammatory bowel disease presents a major risk factor for colon cancer with the most common forms of this disorder being Crohn's disease andulcerative colitis," said Dr. Susanne Talcott, Texas A&M AgriLife Research scientist in a university statement. Furthermore, she said, "colorectal cancer can develop from precursor lesions that can be caused by inflammatory bowel disease over periods of 10 to 15 years, which provides an extended time for preventive measures. Multiple studies have previously demonstrated the health benefits of secondary plant compounds in fruits and vegetables including pomegranate, citrus and curcuminoids, and polyphenolics have been found to reduce inflammatory processes in chronic diseases such as cardiovascular disease, cancer and inflammatory bowel disease (IBD). But, "few human clinical studies using polyphenolics in the treatment of inflammatory bowel disease have been conducted." she said. So Talcott and her team did just that,investigating the consumption of mangoeswhich are high in polyphenols mangiferin, catechins, quercetin, … Continue reading →

Shire PLC (SHPG) lowered its full-year sales expectations Thursday as it braced for a new low-cost competitor to its ulcerative colitis drug Lialda. However, the Dublin-based biopharmaceutical company brightened its profit outlook, due to better-than-expected cost savings from its $32 billion acquisition of Baxalta in 2016. Shire said it now expected full-year revenue to come in at $14.3 billion to $14.6 billion, compared with earlier expectations of $14.5 billion to $14.8 billion. It forecast non-GAAP (Generally Accepted Accounting Principles) diluted earnings per American Depository Receipt of $14.80 to $15.20 for the full year, versus its previous guidance of $14.60 to $15.20. Shire posted net income of $240 million for the three months to June 30, compared with a $162 million loss a year earlier, when earnings were hit by costs related to its Baxalta purchase. Revenue climbed 54% to $3.75 billion, largely reflecting a bigger contribution from products that were previously sold by Baxalta. Continue Reading Below ADVERTISEMENT Analysts had expected net income of $768 million and revenue of $3.67 billion. The year-earlier period only included around one month's sales from Baxalta, which Shire formally acquired on June 3 in 2016. -Write to Denise Roland at denise.roland@wsj.com Shire PLC (SHP.LN) … Continue reading →

DUBLIN, August 3, 2017 /PRNewswire/ -- The "Ulcerative Colitis Therapeutics Pipeline Analysis, 2017" report has been added to Research and Markets' offering. Ulcerative colitis is a chronic inflammatory disease, which basically affects colonic mucosa. The main identified symptoms of the disease are bloody diarrhea, abdominal cramps and fatigue. Some of the other symptoms include, fever, vomiting, anorexia, abdominal distension and bloating. The leading cause of ulcerative colitis is the imbalance in regulation of gastrointestinal immune system. According to the International Society for Pharmacoeconomic and Outcomes Research journal named as value in health, the prevalence of ulcerative colitis has increased from 243 to 263 per 100,000 people each year in the U.S. Ulcerative colitis usually affects the upper layer of all parts of intestine mostly in colon and rectum. The main causes of the disease are genetic susceptibility and environmental factors such as, microbiological, smoking, immunological and psychological factors. The treatment of ulcerative colitis includes tumor necrosis factor inhibitors, such as adalimumab, golimumab and infliximab which were approved for treatment of moderate to severe form of ulcerative colitis in patients who has failed to respond to the other conventional therapies such as, corticosteroids, mesalazine and 5-Aminosalicylic acid. The 5-Aminosalicylic acid is … Continue reading →

Crohns disease is a chronic inflammatory bowel disease which can affect anyone of any age or gender, although it predominantly impacts people between the ages of 16 to 30. At least 115,000 people in the UK have Crohns disease and around one in 10,000 people are newly diagnosed every year, according to charity Crohns and Colitis UK. Causes of Crohns disease are unknown, but experts suggest it could be a combination of factors including genetics, the immune system or smoking. The disease is not currently curable but there are a number of treatments for sufferers. NHS Choices said people with Crohns disease often have a disrupted immune system, which sends a protein to kill all bacteria - regardless of whether they are beneficial to the gut. There can be months where people dont experience any symptoms but people can experience flare ups. Flare ups can also be triggered by diet. Symptoms of Crohn's disease can cause diarrhoea, abdominal pain, fatigue and fever, mouth ulcers, lack of appetite and anaemia. In ulcerative colitis, tiny ulcers develop on the surface of the lining of the large bowel. Ulcerative colitis only affects the colon (large intestine) but Crohn's disease can affect any part … Continue reading →

TORONTO, Aug. 1, 2017 /CNW/ - Crohn's and Colitis Canada is pleased to announce its Grants-in-Aid and Innovations in Inflammatory Bowel Disease (IBD) Grant recipients. Seven Grants-in-Aid have been awarded to advance prevention, treatments, health policy and to ultimately find cures for Crohn's disease and ulcerative colitis. Two researchers have been awarded Innovations Grants, which fund novel approaches to IBD research. "Funding research is at the foundation of our mission to find the cures for Crohn's and colitis, and it's having a huge impact," says Mina Mawani, President & CEO of Crohn's and Colitis Canada. "Crohn's and Colitis Canada is one of the top charity funders of Crohn's and colitis research in the world, and that research is leading to improvements in treatment and care." Grants-in-Aid of Research and Innovations Grants are awarded every year to researchers whose proposals have a clear connection to improved care for those affected by Crohn's or colitis. Recipients hail from across the country and are determined to better the lives of the 250,000 Canadians living with these chronic diseases. 2017 Grants-in-Aid of Research Award Recipients: 2017 Innovations in IBD Grant Recipients: For more information about the selection process and Crohn's and Colitis Canada, visit: … Continue reading →

The study byDr. Susanne Talcott and her team showedmango consumption could be ausefuladjuvant treatmentforindivuduals withinflammatory bowel disease. Credit: Texas A&M AgriLife Research photo Initial results of a study by researchers in the department of nutrition and food science at Texas A&M University in College Station show mango consumption has a positive impact on people with inflammatory bowel disease. Dr. Susanne Talcott, Texas A&M AgriLife Research scientist, and others recently investigated the use of fresh mangoes as an adjuvant to conventional therapy in mild to moderate inflammatory bowel disease. "Inflammatory bowel disease presents a major risk factor for colon cancer with the most common forms of this disorder being Crohn's disease and ulcerative colitis," Talcott said. "Previous studies indicate that IBD affects about 1.5 million individuals in the U.S., about 2.2 million in Europe and many more in other countries." The American Cancer Society estimated in 2016 there were 134,490 new cases of colorectal cancer in the U.S. and these were responsible for 49,190 deaths. "Colorectal cancer can develop from precursor lesions that can be caused by inflammatory bowel disease over periods of 10 to 15 years, which provides an extended time for preventive measures," she said. Talcott said multiple studies … Continue reading →

New drug Renflexis (infliximab-abda), a therapy for ulcerative colitis and Crohns disease, is being launched in the U.S., South Koreas Samsung Bioepis recently announced. Renflexisis a biosimilar of the anti-inflammatory drug Remicade(infliximab) and is being commercialized in the U.S. by Merck. Biosimilars are therapies with no clinically relevantdifferences to a biological reference product previously approved by the U.S. Food and Drug Administration (FDA). They present almost identical structure and activity to the reference product, and can be produced when the original productspatentexpires. Renflexis was approved by the FDA in April 2017 as an injectable 100 mg dose to treat a number of autoimmune diseases (where the bodys immune system attacks healthy cells), including ulcerative colitis and Crohns disease. Renflexis may also be used by people with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. For Crohns disease and ulcerative colitis, Renflexis is indicated to reduce signs and symptoms and achieve stable clinical remission in adult patients with moderate to severe disease who do not show successful response to conventional therapy. Renflexis taken for ulcerative colitis also aims to maintain mucosal healing (a measure of clinical activity) and eliminate corticosteroid use. Renflexis is also recommended for pediatric Crohns disease in … Continue reading →

NEW DELHI: Drug firm Zydus Cadila today said it has received final approval from US health regulator for generic Mesalamine delayed-release tablets used for treatment of ulcerative colitis. The company has received final approval from the United States Food and Drug Administration (USFDA) for Mesalamine delayed-release tablets in the strength of 800 mg, Zydus Cadila said in a statement. The drug will be manufactured at the group's formulation manufacturing facility at Moraiya, it added. The group has received 27 final abbreviated new drug application (ANDA) approvals from the USFDA and 2 tentative ANDA approvals since January 2017, Zydus Cadila said. The group now has more than 130 approvals and has so far filed over 300 ANDAs since the commencement of the filing process, it added. Mesalamine delayed-release tablets are indicated for the treatment of mildly to moderately active ulcerative colitis and for the maintenance of remission of ulcerative colitis. Shares of Cadila Healthcare, the listed entity of the group, were trading 2.51 per cent up at Rs 545 per scrip in the afternoon trade on BSE. View post: Zydus Cadila gets USFDA nod for its ulcerative colitis drug - Economic Times … Continue reading →